Physicians’ Opinions Survey on FDA’s Bydureon Approval

Report Description

Physicians were asked to assess their impressions of Bydureon in terms of efficacy, safety, tolerability, expected use, and other important factors. Key questions are broken down by specialty or familiarity to highlight difference in physician perceptions


Datamonitor anticipates that the initial enthusiasm will ultimately be muted once physicians gain experience with the drug. Nevertheless, a once-weekly antidiabetic agent clearly represents an attractive option for type 2 diabetes patients, and physicians expect the drug to be a welcome addition to their armamentarium.

FDA’s Bydureon Approval

Published: February 2012
: Single User License US$3800            Corporate User License – US$9500

                    Request Sample

Your key questions answered
  • Assess physicians’ opinions of Bydureon as compared with Amylin’s twice-daily Byetta (exenatide) and Novo Nordisk’s once-daily Victoza (liraglutide)
  • Determine physicians’ expectations for Bydureon’s uptake, line of therapy, and use in combination with other antidiabetics
  • Evaluate how Bydureon may expand the overall market for GLP-1 agonists

Table of Contents


Limited familiarity with PCPs could present a marketing challenge
Impressions of Bydureon’s efficacy differ based on familiarity
Tolerability issues trump safety concerns among physicians familiar with Bydureon
High expectations for Bydureon use will likely come down with increased experience
Endocrinologists expect to use Bydureon in earlier line of therapy compared to PCPs
Combination use with oral antidiabetics is likely
Physicians expect Bydureon to expand the GLP-1 agonist market

Report methodology
Datamonitor consulting


List of Figures

Figure: On average, how many patients with type 2 diabetes do you treat per month?
Figure: How familiar are you with Bydureon (once-weekly exenatide)?
Figure: For each attribute below, please select the one drug that you would prefer to prescribe, based on performance (or predicted performance) on that attribute
Figure: Please select the one drug that you would prefer to prescribe, based on efficacy (HbA1c lowering ability)
Figure: Please rank the following potential safety (and tolerability) issues you are most concerned about with Bydureon on a scale of 1 to 7, where 1 is the issue of greatest concern and 7 is the issue of least concern
Figure: Please select the one drug that you would prefer to prescribe, based on injection device
Figure: Where in the treatment algorithm do you think you will most commonly prescribe Bydureon?
Figure: Please consider your hypothetical Bydureon-treated patient population a year post-launch. What percentage of the Bydureon-treated patient population do you expect to have previously been treated with each of the following options?
Figure: Please choose up to three drug classes with which Bydureon could be used in combination. If there are more than three classes, please select the three most likely
Figure: Please give your opinion on how the introduction of Bydureon, and any other market trends, will impact on the number of patients on GLP-1 agonists in the US

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
More Reports
Title Price Buy Now

Global Schizophrenia Therapeutics Market 2014-2018

Schizophrenia is a chronic brain disorder that severely affects the quality of life of a patient by disturbing the normal functioning of the brain. Psychotic symptoms and a diminished range of expression of emotions are the characteristics of schizophrenia. The exact etiology of schizophrenia is still not known. In men, it appears in the late teens or early 20s, and in women in the late 20s or early 30s. However, most of the symptoms of this disorder can be managed with medication and psychological help. TechNavio's analysts forecast the Global Schizophrenia Therapeutics market to grow at a CAGR of 2.82 percent over the period 2013-2018. Covered in this Report This report covers the present scenario and the growth prospects of the Global Schizophrenia Therapeutics market for the p......

Global Pulmonary Drug Delivery Systems Market 2015-2019

Pulmonary delivery of drugs leads to the deposition of drugs in the lungs and subsequent local or systemic therapeutic activity. The pulmonary route of administration for the non-invasive delivery of drugs is mostly preferred because of the large surface area for absorption, high blood circulation, and high permeability rate. Pulmonary drug delivery offers various advantages over peroral routes, such as bypass of hepatic first-pass metabolism, quick onset of action, and low enzymatic activity. Pulmonary delivery of drugs can be achieved by intranasal administration or oral inhalative administration, the latter being more effective. Oral inhalative administration includes intratracheal inhalation and intratracheal instillation. Oral inhalation delivers the aerosolized drug using devices suc......

Global Oncology Biosimilars Market 2014-2018

Biosimilars are follow-on versions of biological medicines that are developed after the expiry of the patent protection on the original product. Biosimilar medicines have a mechanism of action that is similar to that of the original biological medicines. Though biosimilars have many similarities to the innovator product, they are not an exact copy of the reference biopharmaceutical product. Currently, biosimilars are being incorporated into oncology treatment practices. The biosimilars used in oncology in the supportive care setting are known as oncology biosimilars. TechNavio's analysts forecast the Global Oncology Biosimilars market to grow at a CAGR of 29.87 percent over the period 2013-2018. Covered in this Report This report covers the present scenario and the growth prospect......

Global Irritable Bowel Syndrome Market 2015-2019

Irritable bowel syndrome is a common disorder of the digestive system causing abdominal cramps, discomfort, bloating, constipation, and diarrhea. Inflammatory bowel disease, which is a chronic disease with recurrent immune response and inflammation of the GI tract, is sometimes confused with irritable bowel syndrome. The symptoms of irritable bowel syndrome generally appear in a patient aged around 30 years. According to the CDC, prominent symptoms of irritable bowel syndrome include severe bloating, severe stomach cramps or abdominal pain, lower back pain, groin pain, heartburn, acidity, shooting pain in the legs, and lightheadedness after eating. TechNavio's analysts forecast the Global Irritable Bowel Syndrome market to grow at a CAGR of 14.04 percent over the period 2014-2019. Co......

Global Antisense and RNAi Therapeutics Market 2015-2019

Antisense and RNAi therapeutics are new innovative therapeutics options that are used in the treatment of serious chronic and rare diseases. RNAi is a RNA-based gene silencing process in which RNA molecules inhibit gene expression by destructing definite mRNA molecules. Antisense technology involves the synthesis of a strand of nucleic acid that would bind to an mRNA or to a splicing site on pre-mRNA and inactivates it effectively. RNAi and antisense are two predominant technologies used by pharmaceutical companies, research institutes, and others for various applications such as research, diagnostics, and therapeutics. RNAi therapeutics have a large scope in the treatment of diseases such as cancer and neurodegenerative disorders. There are two types of RNA molecules used in the RNAi tech......

Medical Technology Market in Europe 2014-2018

Medical technology refers to technology used in individuals suffering from wide range of conditions to ensure better health of the patients. It involves the entire pathway from diagnosis to cure of the patient. The medical technologies bring healthy life years, prevents disease progression, and show a vital role in healthcare. The Medical technology includes: software solutions, medical devices, imaging, biological derived devices, and diagnostic equipment; technologies such as active and non-active implantable, aesthetic and respiratory, IVD, dental, electromechanical medical, and therapeutic radiation. Many people depend on medical technology at home, hospital and nursing homes for life-supporting machines, wheelchairs, insulin pens, pregnancy tests: more than five million medtech produc......

Global Dialysis Services Market 2015-2019

A kidney is an essential organ of the body that excretes waste, salt, and excess water from the body. Kidney failure or an injury to the kidneys can cause serious problems such as a blood clot, infection, and multiple myelomas. Dialysis is a treatment that works like an artificial kidney by eliminating waste and excess water from the body. During dialysis, the blood of an individual is cleaned by the removal of excess waste such as creatinine and nitrogen that builds up in the bloodstream. Dialysis is done with the help of a dialysate fluid. Dialysate is a mixture of chemicals and pure water that helps remove waste from the blood without removing the substances that the body needs. TechNavio's analysts forecast the Global Dialysis Services market to grow at a CAGR of 4.65percent over th......

Global Cushing’s Syndrome Therapeutics Market 2015-2019

Cushing's syndrome is a condition caused by the prolonged exposure to very high levels of cortisol. This can occur because of the consumption of glucocorticoid drugs or diseases that result in excess cortisol, ACTH, and CRH secretion. Harvey Cushing described the pathophysiology of this condition in 1932. It is more common in women than in men. Cushing's syndrome is also known as hypercortisolism, hypercorticism, hyperadrenocorticism, or Itsenko-Cushing syndrome. Some of the common symptoms of Cushing's syndrome are increase in weight, facial acne, cognitive disorders, and vulnerability to superficial fungus infections, growth of a mass around the collarbone or back of the neck, commonly known as the "buffalo hump," and puffy face or "moon face". Other symptoms include sweating, polyuria, ......

Global Cardiovascular Information System Market 2015-2019

A CVIS is a collection of research and clinical data gathered with the help of unique software, which facilitates information and support, and provides a complete medical record of patients in the cardiovascular field. The CVIS is used to endorse data with a high level of evidence-based quality. The CVIS improves patient safety and provides quality care by eliminating duplicate entries and reducing errors, besides improving efficiency. The productivity of the CVIS is high as it has access to all the cardiac images of a patient from anywhere along with relevant information of that cardiac patient. The CVIS finds application in the following fields: echocardiography, electrocardiography, electrophysiology, catheterization labs, and other CVIS solutions such as cardiac CT/MRI, hemodynamics, a......

Global Epilepsy Market 2014-2018

Epilepsy is defined as a spectrum of brain disorders varying from benign symptoms to severe, disabling, and life-threatening symptoms. It can be caused by various factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and birth trauma. However, when the underlying cause of the disease is unidentified, as occurs in majority of the cases, it is known as idiopathic epilepsy. Epilepsy is characterized by repeated occurrence of generalized or focal seizures. Seizures result from an imbalance between the inhibitory and excitatory signals of the brain leading to sudden-onset of excitation. The occurrence of two or more unprovoked seizures is an important criteria to diagnose a person with seizures as being epileptic. TechNavio's analysts forecast the Global E......